摘要
目的:确定是否(1)血浆淀粉样蛋白β之间存在一种关系(Aβ)1 - 40和1-42肽水平,老年人与非遗忘型轻度认知功能损害的脑容积和认知能力(aMCI),(2)血浆Aβ肽水平在不同载脂蛋白E(APOE)ε4携带者和非携带者和(3)纵向变化的认知和大脑体积与Aβ水平相关。方法:伴随aMCI 的受试者(n = 89)与正常认知(N = 126)分别来自Sydney记忆和老龄化研究(Sydney MAS),以非痴呆人群70-90岁的为基础个体研究;39位阿尔茨海默氏病(AD)患者从专业诊所被招募。Sydney MAS参与者接受脑部核磁共振成像扫描,并被19种认知措施评估和ApoE基因ε4。等离子体水平的Aβ1-40使用ELISA和1-42量化。结果:Aβ多肽的WAVE1的血浆水平和 Aβ1−42/1-40比率在AD和aMCI 中比例较低,并且Aβ1−42与全球认知及海马体积呈负相关的白质高信号呈负相关。一个 Aβ1-40和 Aβ1-42的关系主要是分别观察ε4等位基因携带者和非携带者。纵向分析显示在全球认知和记忆更大的跌幅对Aβ1−42的最高昆泰和比率测量。结论:血浆β水平和一个 Aβ1−42 / 1比是认知及海马体积有关,与一个 Aβ1-40和 Aβ1-42在ε4携带者和非携带者微分关系。这些数据支持AD病理学Aβ模型,并表明等离子体Aβ措施可以作为生物标志物。
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
Current Alzheimer Research
Title:The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study
Volume: 13 Issue: 3
Author(s): Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev
Affiliation:
关键词: Aβ1-40、 Aβ1-42、APOE、脑体积、认知、神经心理学测试、MRI、血浆、白质高信号。
摘要: Objectives: Determine whether (1) a relationship exists between plasma amyloid-β (Aβ)1- 40 and 1-42 peptide levels, brain volumetrics and cognitive performance in elderly individuals with and without amnestic mild cognitive impairment (aMCI), (2) plasma Aβ peptide levels differ between apolipoprotein E (APOE) ε4 carriers and non-carriers and (3) longitudinal changes in cognition and brain volume relate to Aβ levels. Methods: Subjects with aMCI (n = 89) and normal cognition (n = 126) were drawn from the Sydney Memory and Aging Study (Sydney MAS), a population based study of non-demented 70-90 year old individuals; 39 Alzheimer’s disease (AD) patients were recruited from a specialty clinic. Sydney MAS participants underwent brain MRI scans and were assessed on 19 cognitive measures and were APOE ε4 genotyped. Plasma levels of Aβ1-40 and 1-42 were quantified using ELISA. Results: Wave1 plasma levels of Aβ peptides and Aβ1−42/1-40 ratio were lower in aMCI and AD, and Aβ1−42 was positively associated with global cognition and hippocampal volume and negatively with white matter hyperintensities. The relationships of Aβ1-40 and Aβ1-42 were predominantly observed in ε4 allele carriers and non-carriers respectively. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1−42 and the ratio measure. Conclusion: Plasma Aβ levels and the Aβ1−42/1-40 ratio are related to cognition and hippocampal volumes, with differential associations of Aβ1-40 and Aβ1-42 in ε4 carriers and non-carriers. These data support the Aβ sink model of AD pathology, and suggest that plasma Aβ measures may serve as biomarkers of AD.
Export Options
About this article
Cite this article as:
Anne Poljak, John D. Crawford, George A. Smythe, Henry Brodaty, Melissa J. Slavin, Nicole A. Kochan, Julian N. Trollor, Wei Wen and Karen A. Mather, Amelia A. Assareh, Pek C. Ng, Perminder S. Sachdev , The Relationship Between Plasma Aβ Levels, Cognitive Function and Brain Volumetrics: Sydney Memory and Ageing Study, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150202
DOI https://dx.doi.org/10.2174/1567205013666151218150202 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The Phosphoinositide Signal Transduction Pathway in the Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Circulating Exosomes and Their Role in Stroke
Current Drug Targets Relationship between Inflammatory Mediators, Aβ Levels and ApoE Genotype in Alzheimer Disease
Current Alzheimer Research Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Auditory Verbal Learning Test is Superior to Rey-Osterrieth Complex Figure Memory for Predicting Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism Does an Interdisciplinary Network Improve Dementia Care? Results from the IDemUck-Study
Current Alzheimer Research The Peripheral Nervous System and the Pathogenesis of Prion Diseases
Current Molecular Medicine Body Mass Index (BMI) and Cognitive Functions in Later Life
Current Alzheimer Research γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Combining Feature Extraction Methods to Assist the Diagnosis of Alzheimer’s Disease
Current Alzheimer Research N-Substituted Aryl Sulphonamides as Potential Anti-Alzheimer’s Agents: Design, Synthesis and Biological Evaluation
Current Computer-Aided Drug Design Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Quantitative Machine Learning Analysis of Brain MRI Morphology throughout Aging
Current Aging Science Smoking and Cognition
Current Drug Abuse Reviews